Tamai H, Nagai K, Uehata S, Komaki G, Kiyohara K, Miyauchi A, Kuma K, Kumagai L F, Nagataki S
Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Exp Clin Endocrinol. 1990 Dec;96(3):279-87. doi: 10.1055/s-0029-1211020.
T3 nonsuppressibility and TSH nonresponsiveness to TRH are characteristics of untreated hyperthyroid Graves' disease. Although the tests are commonly restored to normal during antithyroidal drug therapy, dissociation of TRH and T3 suppression tests have been observed in euthyroid Graves' disease and during drug therapy. Abnormalities of pituitary-thyroidal regulation and persistence of thyroid autoimmune disease have been found in Graves' patients following various modalities of therapy. The present study investigated in vivo sensitivity to endogenous TSH of thyroids in 144 Graves' disease patients following treatment with subtotal thyroidectomy, 131I, or antithyroidal drugs. After administration of TRH, thyroidal sensitivity to TSH was determined by the following: delta T3 (peak T3 minus basal T3), % increase in T3 (peak over basal), and the ratio of delta T3 to delta TSH. Significant differences in sensitivity to TSH in T3 nonsuppressible patients were found compared to suppressible patients regardless of their TSH responses to TRH or modality of therapy. These data suggest that measurements of serum T3 and TSH following TRH administration to determine in vivo thyroidal sensitivity may be substituted for the T3 suppression test as a confirmatory test for Graves' disease or as a prognosticator of relapse following therapy.
T3不被抑制以及TSH对促甲状腺激素释放激素(TRH)无反应是未经治疗的甲状腺功能亢进型格雷夫斯病的特征。尽管在抗甲状腺药物治疗期间这些检查通常会恢复正常,但在甲状腺功能正常的格雷夫斯病患者以及药物治疗期间,已观察到TRH和T3抑制试验结果出现分离。在格雷夫斯病患者接受各种治疗方式后,发现存在垂体 - 甲状腺调节异常以及甲状腺自身免疫性疾病的持续存在。本研究调查了144例格雷夫斯病患者在接受甲状腺次全切除术、131I或抗甲状腺药物治疗后,甲状腺对内源性TSH的体内敏感性。给予TRH后,通过以下指标确定甲状腺对TSH的敏感性:ΔT3(峰值T3减去基础T3)、T3增加百分比(峰值相对于基础值)以及ΔT3与ΔTSH的比值。无论TSH对TRH的反应或治疗方式如何,与可抑制患者相比,T3不可抑制患者对TSH的敏感性存在显著差异。这些数据表明,给予TRH后测量血清T3和TSH以确定体内甲状腺敏感性,可替代T3抑制试验作为格雷夫斯病的确诊试验或治疗后复发的预测指标。